Agenus’ (AGEN) Neutral Rating Reaffirmed at HC Wainwright

HC Wainwright restated their neutral rating on shares of Agenus (NASDAQ:AGEN) in a research note published on Thursday morning,Benzinga reports.

A number of other equities analysts have also recently issued reports on AGEN. StockNews.com cut Agenus from a “hold” rating to a “sell” rating in a report on Monday, August 12th. B. Riley cut their price objective on Agenus from $42.00 to $18.00 and set a “buy” rating for the company in a report on Wednesday, August 14th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the company. According to MarketBeat, Agenus currently has an average rating of “Hold” and a consensus price target of $10.00.

Agenus Trading Down 8.5 %

AGEN opened at $3.14 on Thursday. The stock has a 50-day moving average price of $4.06 and a 200-day moving average price of $7.91. Agenus has a 12-month low of $2.50 and a 12-month high of $19.69. The stock has a market capitalization of $73.66 million, a P/E ratio of -0.28 and a beta of 1.24.

Institutional Investors Weigh In On Agenus

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its position in Agenus by 13.7% during the 1st quarter. Vanguard Group Inc. now owns 34,401,122 shares of the biotechnology company’s stock valued at $19,953,000 after purchasing an additional 4,134,232 shares during the last quarter. Walleye Capital LLC bought a new position in Agenus during the 3rd quarter valued at approximately $1,003,000. Price T Rowe Associates Inc. MD raised its position in Agenus by 52.4% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 357,915 shares of the biotechnology company’s stock valued at $208,000 after purchasing an additional 123,058 shares during the last quarter. Federated Hermes Inc. bought a new position in Agenus during the 2nd quarter valued at approximately $1,921,000. Finally, Susquehanna Fundamental Investments LLC bought a new position in Agenus during the 2nd quarter valued at approximately $1,050,000. Institutional investors own 61.46% of the company’s stock.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.